NCT07640022

Brief Summary

CRT improves outcomes in heart failure patients, but class II candidates (i.e. patients presenting non-LBBB or narrow LBBB patterns) benefit less from this treatment. The RESYNC-PETCT study explores advanced imaging guidance using 82Rubidium PET-CT and cardiac CTV to target coronary sinus lead placement with the aim to improve CRT response in this specific patient population. All genders will be included in this study. However, gender is not considered a variable in this clinical trial. Patients participating in this study will benefit from an individualized approach to CRT implantation. The nuclear and radiological tests proposed in this research project will imply an additional radiation exposure compared to the standard care. However, the total additional radiation dose will remain below the recommended threshold for clinical trials so that the radiological risks associated to these investigations appear negligible and are counterbalanced by the improvement in LVEF and NYHA expected from a targeted coronary sinus lead positioning. The objective of the RESYNC-PETCT study is to demonstrate that optimising the coronary sinus lead implantation by using combined data from 82Rubidium PET-CT scan and cardiac CTV reconstruction is a feasible approach to improve the LV electrical and mechanical synchronicity and therefore the clinical response in patients presenting non-LBBB patterns or LBBB patterns with QRS duration \< 150ms.

Trial Health

65
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
20

participants targeted

Target at below P25 for not_applicable heart-failure

Timeline
18mo left

Started Jun 2026

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

June 5, 2026

Completed
5 days until next milestone

First Posted

Study publicly available on registry

June 10, 2026

Completed
5 days until next milestone

Study Start

First participant enrolled

June 15, 2026

Completed
1.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 15, 2027

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 15, 2027

Last Updated

June 10, 2026

Status Verified

June 1, 2026

Enrollment Period

1.5 years

First QC Date

June 5, 2026

Last Update Submit

June 5, 2026

Conditions

Keywords

Cardiac resynchronisation therapy

Outcome Measures

Primary Outcomes (1)

  • Feasibility of guided coronary sinus lead placement/Improvement in LVEF ≥ 5% measured by TTE and reduction in NYHA ≥ 1

    CRT implant day and 3/6 months follow-up

Secondary Outcomes (1)

  • Improvement in mechanical dyssynchrony assessed by phase analysis of 82Rubidium PET-CT scan/Differences in LVEF, mechanical dyssynchrony, and NYHA class among the study patients implanted with a BIV-CRT approach and the study patients stimulated in LBBAP

    6 months

Study Arms (1)

Heart failure patients with CRT indications

EXPERIMENTAL
Device: CRT-P/CRT-D implantation

Interventions

CRT-P/CRT-D implantation

Heart failure patients with CRT indications

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Symptomatic heart failure (NYHA class II, III and IV) despite optimal medical treatment
  • LVEF ≤ 35%
  • Sinus rhythm
  • Non LBBB pattern on 12-lead ECG with QRS \> 130 ms
  • LBBB pattern on 12-lead ECG with QRS \> 130 ms and \< 150 ms
  • Patient is able to understand the nature of the research project and to provide written informed consent.
  • Patient accepts to be informed about incidental findings discovered by 82Rubidium PET-CT scan and cardiac CTV that imply clinical management

You may not qualify if:

  • Pregnancy (as per standard procedure)
  • Age less than 18 years
  • Severe chronic kidney disease (Glomerular filtration rate \< 30mL/min) contraindicating a cardiac CTV
  • Life expectancy of less than 12 months.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Heart Failure

Condition Hierarchy (Ancestors)

Heart DiseasesCardiovascular Diseases

Central Study Contacts

Giulia Domenichini, MD PhD

CONTACT

Christel C Kamani

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

June 5, 2026

First Posted

June 10, 2026

Study Start

June 15, 2026

Primary Completion (Estimated)

December 15, 2027

Study Completion (Estimated)

December 15, 2027

Last Updated

June 10, 2026

Record last verified: 2026-06

Data Sharing

IPD Sharing
Will not share